乳腺癌治疗中应用多西他赛联合表柔比星新辅助化疗的效果分析及评定

沈颖　周剑

【摘要】 目的：探讨表柔比星联合多西他赛治疗乳腺癌的应用效果。方法：选择2013年6月-2014年11月乳腺癌患者90例，根据治疗方法分两组。两组均应用多西他赛联合表柔比星新辅助化疗，对照组先采用表柔比星，之后应用多西他赛，观察组则先用多西他赛，之后应用表柔比星。比较两组乳腺癌治疗效果，生存时间，治疗前后患者卡氏评估分值、体力状况、FACT-B生存质量评分。结果：观察组乳腺癌治疗效果优于对照组，差异有统计学意义（P<0.05）；观察组生存时间长于对照组，差异有统计学意义（P<0.05）；治疗前两组卡氏评估分值、体力状况、FACT-B生存质量评分相近（P>0.05）；治疗后观察组卡氏评估分值、体力状况、FACT-B生存质量评分均优于对照组，差异均有统计学意义（P<0.05）。结论：乳腺癌治疗中应用多西他赛联合表柔比星新辅助化疗的效果确切，但药物应用顺序可影响治疗效果，推荐先应用多西他赛再用表柔比星，以更好改善病情和生活质量。

【关键词】 表柔比星； 多西他赛； 乳腺癌； 应用效果

doi：10.14033/j.cnki.cfmr.2018.22.003 文献标识码 A 文章编号 1674-6805（2018）22-000-03

Effect Analysis and Evaluation of Docetaxel Combined with Epirubicin Neoadjuvant Chemotherapy in the Treatment of Breast Cancer/SHEN Ying，ZHOU Jian.//Chinese and Foreign Medical Research，2018，16（22）：-8

【Abstract】 Objective：To investigate the effect of Epirubicin combined with Docetaxel in the treatment of breast cancer.Method：90 cases of breast cancer from June 2013 to November 2014 were divided into two groups according to the treatment method.The two groups were treated with Docetaxel plus Epirubicin neoadjuvant chemotherapy.The control group was treated with Docetaxel after the first use of Epirubicin.The observation group was treated with Docetaxel then followed Epirubicin.The treatment effect of two groups of breast cancer was compared，the time of survival，the score of Karnofsky evaluation before and after treatment，the physical condition and the quality of life of FACT-B were compared before and after the treatment.Result：The observation group of breast cancer treatment was higher than the control group（P<0.05）；the observation group of survival time was longer than the control group（P<0.05）.The two groups before treatment，the Karnofsky evaluation score，physical status，FACT-B quality of life score were similar（P>0.05）；after treatment，the observation groups Karnofsky evaluation score， physical status，FACT-B quality of life score were better than those of the control group（P<0.05）.Conclusion：Docetaxel combined with Epirubicin neoadjuvant chemotherapy is effective in the treatment of breast cancer，but the sequence of drug application can affect the therapeutic effect.It is recommended that Docetaxel should be applied first，and then Epirubicin，so as to improve the condition and quality of life.

【Key words】 Epirubicin； Docetaxel； Breast cancer； Application effect

First-authors address：Xianning Central Hospital，Xianning 437100，China

乳腺癌患者近年來越来越多，是女性常见的恶性肿瘤之一[1]。乳腺癌首选手术治疗，而辅术前新辅助化疗和术后化疗也非常重要，有利于进一步杀灭残留肿瘤细胞，降低复发率。但目前关于新辅助化疗方案的选择仍存在争议。多西他赛是一种紫杉类抗肿瘤药物，其抗癌作用在于抑制微管解聚，强化微管蛋白聚合作用。而表柔比星为蒽环类抗癌药物，可影响DNA和RNA合成[1-2]。为了探讨乳腺癌患者的有效新辅助化疗方法，本研究选择2013年6月-2014年11月乳腺癌患者90例，根据治疗方法分两组，分析了表柔比星联合多西他赛治疗乳腺癌的应用效果，报告如下。